Although the artwork surrounding this blog site segues from the image of a court-house to a baseball motif, reflecting my intent to moderate the law-related content of the site with occasional forays into baseball commentary (an admittedly mindless but none-the-less … Continue reading
Stephen Honig
On July 24 I posted about a lawsuit which emphasizes the risks of companies raising capital through finders unregistered with FINRA under Federal securities laws. It must be noted that the much-discussed SEC no-action letter of earlier this year provided some … Continue reading
Just a few thoughts on what the recent couple of months has brought us on the lawyering front: First, the focus on cyber security has, if anything, intensified. Between the news articles recounting hacks of businesses and governments and the proliferation of … Continue reading
Recently, much has been published (including an article by me appearing in In-House) about the possible loosening of SEC restriction by not requiring finders in M&A situations to be SEC-registered. As I have noted, this possible SEC relief is limited; … Continue reading
At the National Association of Corporate Directors-New England breakfast on Tuesday, one guest had the temerity to suggest to the Director of SEC’s Boston Office, and to Secretary of the Commonwealth Bill Galvin (who controls the State’s Securities Division), … Continue reading
Akamai Technologies, Inc. of Cambridge, Massachusetts is one of the true internet success stories, with $1,600,000,000 of annual revenues and EBITDA of about 44%. A disciplined pursuit of M&A opportunities has driven part of this growth, as reported by Vice … Continue reading
All directors, whether of non-profits or for-profits, face the same problem: how to focus on the essence of board function, strategy, while besieged with the pressures of an increasingly complex world? Some interesting perspectives surfaced at the National Association of … Continue reading
How can you drive down the cost of medical services? This is my final post based upon the MassMEDIC Annual Conference held on May 7th at the UMass Boston Campus. The goal, per the conference, is not to bring down … Continue reading
I have previously posted on changes in the medical device clinical trial landscape noted at the MassMEDIC Annual Conference held May 7th at UMass Boston. Another area of discussion focused on financing emerging medical device companies. It is no secret … Continue reading
The medical device marketplace is all about FDA clinical trials, determining whether a device creates good patient outcomes and is reimbursable, and the avoidance of economic risk. These factors, interestingly, bear in a significant way on the manner in which … Continue reading